Triple-Negative Breast Cancer (TNBC) Recruiting Phase 1 Trials for Docetaxel (DB01248)

Also known as: Triple-negative Breast Cancer

DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting1 IdentifierTitlePurposeDrugs
NCT03893955A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid TumorsTreatment
NCT03829436TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced CancersTreatment